One of the first focuses of organ-chip specialist Emulate (Boston) was to reduce the need for animal testing over time. Its technology can simulate tissue-tissue interfaces within organs using human cells. But the potential of the organ chips to yield mechanistic insights for drug discovery and understanding toxicities has become more evident over time. The…
Organ chip firm Emulate debuts second-generation culture module
Boston-based Emulate has introduced the Zoë-CM2 culture module, which prolongs the life of cells within the company’s organ chips. The module can automate the conditions for culturing up to 12 chips. The culture module is a component of Emulate’s Human Emulation System, which integrates instruments, consumables and software. Emulate, which is a spinoff from the…
Why Emulate launched a colon intestine chip
Emulate has debuted what it terms a “colon intestine chip” targeted at pharma and biotech companies, academics and other researchers. The company believes the system will accelerate the identification of drug candidates to treat inflammatory damage in the colon. The technology could be a boon for understanding inflammatory bowel disease, which approximately 1.6 million people in…
As organs-on-chips advance, their potential for drug discovery grows
Engineered microchips with living human cells have the potential to accelerate drug development and replace animal testing, said Dr. Donald Ingber, the founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University. The organ-on-a-chip technology could also enable the industry to rethink its business model, Ingber said in a webinar from the…